Tempus AI
The world's largest clinical-molecular AI platform powering precision oncology decisions for physicians and pharma.
Overview
Tempus AI is a Chicago-based health technology company that has built the world's largest library of de-identified clinical and molecular data — spanning genomics, pathology imaging, and real-world patient outcomes — and combines it with proprietary AI models to help oncologists make more precise treatment decisions. Its platform connects to approximately 50% of US oncologists and over 4,500 hospitals, offering next-generation sequencing diagnostics, AI-assisted biomarker prediction from tissue slides (via the Paige Predict suite acquired in 2025), clinical trial matching through the TIME Network, and a physician-facing agentic AI portal called Hub.
Beyond direct clinical use, Tempus licenses its multimodal datasets to more than 200 pharmaceutical and biotech companies through its Lens platform, enabling drug discovery, trial design, and real-world evidence generation. The company went public on Nasdaq (TEM) in June 2024 and reported Q1 2026 revenue of $348 million — a 36% year-over-year increase — with full-year 2026 guidance of $1.59 to $1.60 billion. Its international footprint is anchored by SB Tempus, a joint venture with SoftBank established in 2024 to bring precision medicine AI to Japan.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 16 Jun 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
Use cases
What you can produce with Tempus AI
- NGS genomic sequencing report identifying mutations, fusions, and copy number variants mapped to actionable therapies and FDA-approved treatments
- AI-generated biomarker prediction panel from a single H&E whole-slide image covering 123 biomarkers across 16 cancer types (Paige Predict, ~5 min turnaround)
- Clinical trial match list identifying eligible open trials for a patient's specific molecular and clinical profile via the TIME Network
- De-identified multimodal research dataset (genomics, clinical outcomes, imaging) licensed to pharma teams through the Lens platform
- Hub-generated prior authorization letters and patient-specific clinical summaries drawn from Tempus genomic and longitudinal data
- Minimal residual disease (MRD) monitoring results for tracking treatment response and early recurrence detection in cancer patients
ASEAN Perspective
Tempus AI in Southeast Asia
Tempus AI has no disclosed commercial operations or data partnerships in Southeast Asia as of mid-2026; its only confirmed Asia presence is the SB Tempus joint venture in Japan, established with SoftBank in June 2024, focused on aggregating Japanese clinical and molecular data. ASEAN health systems seeking AI-powered genomics infrastructure will need to look at regional players or Illumina's local distributor network in the interim. Tempus's pharma-facing Lens data platform could theoretically be licensed to APAC biopharma companies, but the data itself is predominantly US-sourced, limiting clinical relevance for Asian patient populations with distinct mutational profiles.
Tempus AI is among the most data-rich precision oncology platforms in existence, with a self-reinforcing flywheel of clinical sequencing, molecular data, and real-world outcomes that no pure-software competitor can easily replicate. Its Q1 2026 results ($348M revenue, 63.8% gross margin, near-breakeven Adjusted EBITDA of -$2.8M) demonstrate that the business model is maturing rapidly, and the Paige digital pathology acquisition meaningfully extends its addressable surface into tissue analysis via the Paige Predict suite launched in January 2026.
The key caveats are structural: pricing is entirely opaque and accessible only through enterprise sales, making it unsuitable for individual clinicians or smaller institutions without institutional contracts. Outside the United States, the platform's reach is nascent — the SB Tempus Japan joint venture is the only confirmed APAC foothold, and Southeast Asia has no disclosed presence. The EPS miss in Q1 2026 (-$0.71 vs. -$0.10 forecast) also underscores that net profitability remains a work in progress despite improving margins. For large US academic medical centers and global pharma R&D teams, Tempus is a compelling tier-one platform; for smaller clinics, APAC health systems, or budget-constrained researchers, alternatives with more accessible pricing may serve better.
What people say
Tempus AI earns high marks for the depth and integration of its clinical-molecular platform, connecting to roughly half of US oncologists and 4,500+ hospitals — a data moat that is genuinely difficult to replicate. The Paige acquisition adds meaningful pathology AI capability. Revenue growth is robust (36% YoY in Q1 2026, $348M) and pharma data-licensing is scaling well, with over $1.1B in total contract value (TCV) from signed data agreements as of December 2025. Deductions come from total pricing opacity, a still-negative net income, a limited APAC footprint (Japan JV only, no Southeast Asia), and the absence of any self-serve tier. A strong tier-one choice for large US health systems and global pharma R&D; less accessible for smaller institutions or Asian health systems.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- Tempus was founded in 2015 after CEO Eric Lefkofsky's wife was diagnosed with breast cancer — he was frustrated by how little AI was being applied to cancer care decisions.
- Paige's foundation model for cancer pathology was trained on almost 7 million digitized slide images, earning it the title of the first million-slide foundation model for cancer.
- The SB Tempus joint venture launched in June 2024 with SoftBank, each investing JPY 15 billion (~$100M USD), signalling precision medicine's push into Japan's aging population market.
- Paige Predict, launched January 2026, can predict the likely presence or absence of 123 biomarkers across 16 cancer types from a single H&E tissue slide — in roughly 5 minutes.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Tempus AI's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Tempus AI unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Tempus AI directly →
Spotted something out of date? Suggest an update →
Alternatives to Tempus AI
More in Research & Data
